Skip to main navigation Skip to search Skip to main content

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.

  • Joshua Bauml
  • , Byoung Chul Cho
  • , Rachel E Sanborn
  • , See full author list in comments

Research output: Other contribution

Fingerprint

Dive into the research topics of 'Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Neuroscience

Immunology and Microbiology

Veterinary Science and Veterinary Medicine

Biochemistry, Genetics and Molecular Biology